Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population

References

• Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. Chronic Disease Indicators (CDI) data. Available from: https://nccd.cdc.gov/cdi/rdPage.aspx?rdReport=DPH_CDI.ExploreByTopic&islTopic=COPD&islYear=9999&go=GO. Accessed April 30, 2021.
   Google Scholar
• Dhamane AD, Moretz C, Zhou Y, et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015;10:2609–2618. doi:10.2147/COPD.S90148
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Mortality in the United States, 2019. NCHS data brief. No 395; 2020. Available from: https://www.cdc.gov/nchs/data/databriefs/db395-H.pdf. Accessed May 14, 2021.
   Google Scholar
• COPD national action plan. Available from: https://www.nhlbi.nih.gov/health-topics/education-and-awareness/COPD-national-action-plan. Accessed January 30, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022 report. Available from: GOLD-REPORT-2022-v1.0-12Nov2021_WMV.pdf(goldcopd.org). Accessed November 19, 2021.
   Google Scholar
• Dalal AA, Patel J, D’Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21(7):575–583. doi:10.18553/jmcp.2015.21.7.575
   PubMed Web of Science ®Google Scholar
• Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228. doi:10.3109/15412555.2010.481697
   PubMedGoogle Scholar
• Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764. doi:10.2147/COPD.S36997
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Evaluation for infection in exacerbations of chronic obstructive pulmonary disease; 2017. UpToDate. Available from: https://www.uptodate.com/contents/evaluation-for-infection-in-exacerbations-of-chronic-obstructive-pulmonary-disease. Accessed January 29, 2021.
   Google Scholar
• Han MK, Dransfield MT, Martinez FJ. Chronic obstructive pulmonary disease definition, clinical manifestations, diagnosis, and staging. UpToDate. Available from: https://www.uptodate.com/contents/chronic-obstructive-pulmonary-disease-definition-clinical-manifestations-diagnosus-and-staging. Accessed January 29, 2021.
   Google Scholar
• Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85–91. doi:10.1016/j.rmed.2017.04.013
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al.; COPDGene Investigators. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324–330. doi:10.1164/rccm.201605-1014OC
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555. doi:10.1513/pats.200709-148ET
   PubMedGoogle Scholar
• Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–150. doi:10.1378/chest.14-2434
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al.; SUMMIT Investigators. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC
   PubMed Web of Science ®Google Scholar
• Genao L, Durheim MT, Mi X, Todd JL, Whitson HE, Curtis LH. Early and long-term outcomes of older adults after acute care encounters for chronic obstructive pulmonary disease exacerbation. Ann Am Thorac Soc. 2015;12(12):1805–1812. doi:10.1513/AnnalsATS.201504-250OC
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2898. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. A dozen facts about medicare advantage in 2020; 2021. Available from: https://www.kff.org/medicare/issue-brief/a-dozen-facts-about-medicare-advantage-in-2020/. Accessed July 29, 2021.
   Google Scholar
• Hanania NA, Sharma G, Sharafkhaneh A. COPD in the elderly patient. Semin Respir Crit Care Med. 2010;31(5):596–606. doi:10.1055/s-0030-1265900
   PubMed Web of Science ®Google Scholar
• Mues KE, Liede A, Liu J, et al. Use of the medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–277. doi:10.2147/CLEP.S105613
   PubMed Web of Science ®Google Scholar
• Medicare savings program. Available from: https://www.medicare.gov/medicare-savings-programs. Accessed July 19, 2021.
   Google Scholar
• Dually eligible beneficiaries under medicare and medicaid. Available from: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/Medicare_Beneficiaries_Dual_Eligibles_At_a_Glance.pdf. Accessed July 19, 2021.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–709. doi:10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097. doi:10.1378/chest.09-2029
   PubMed Web of Science ®Google Scholar
• Niegisch G, Gerullis H, Lin SW, et al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer. 2018;9(8):1337–1348. doi:10.7150/jca.23162
   PubMed Web of Science ®Google Scholar
• Health Resources and Services Administration. Consumer Price Index (CPI) for medical care. Available from: https://www.hrsa.gov/sites/default/files/hrsa/get-health-care/affordable/hill-burton/cpitables.pdf. Accessed June 30, 2021.
   Google Scholar
• Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1019–1031. doi:10.2147/COPD.S199251
   PubMed Web of Science ®Google Scholar
• Palli SR, Zhou S, Shaikh A, Willey VJ. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy. J Manag Care Spec Pharm. 2021;27(5):625–637. doi:10.18553/jmcp.2021.20390
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.005
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. doi:10.1186/1741-7015-11-181
   PubMed Web of Science ®Google Scholar
• Bender BG. Nonadherence to COPD treatment: what have we learned and what do we do next? COPD. 2012;9(3):209–210. doi:10.3109/15412555.2012.679880
   PubMedGoogle Scholar
• Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer 2011. Rockville, MD: Agency for Healthcare Research and Quality; 2013. HCUP Statistical Brief #160. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp. Accessed January 20, 2015.
   Google Scholar
• Haughney J, Lee AJ, Nath M, et al. The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK). Eur Respir J. 2020;56(Suppl 64):4910.
   Google Scholar
• Clinical Trials.gov. Exacerbations and their outcomes (EXACOS international). Available from: https://clinicaltrials.gov/ct2/show/record/NCT04928417. Accessed June 30, 2021.
   Google Scholar